A prospective candidate gene study investigating the relation of genetic variants and HD-MTX pharmacokinetics in osteosarcoma patients identified statistically significant associations between MTX clearance and variants in ABCG2 and UGT1A (Lui et al., 2018). This evidence concerns the gene ABCG2 and osteosarcoma.